Unlock instant, AI-driven research and patent intelligence for your innovation.
Crystal form, preparation method and application of prostaglandin analogue
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
一种晶型、药物的技术,应用在化学制药领域,能够解决前列腺素类化合物稳定性差等问题
Inactive Publication Date: 2013-07-10
SHANGHAI TECHWELL BIOPHARMACEUTICALS CO LTD
View PDF29 Cites 12 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0009] Generally, prostaglandin compounds have poor stability and need to be stored below -20°C. From the perspective of compound stability and purity, there is an urgent need in this field to obtain a stable crystal form of compound I
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
preparation example Construction
[0050] The preparation method of compound I crystal form A
[0051] The present invention also provides a preparation method of crystal form A of the compound represented by formula I.
[0052] In one embodiment provided by the invention, the preparation method of the crystal form A of the compound of formula I comprises the following steps:
[0054] (2) Cool down the temperature of solution 1 or add solvent 2 and stir to precipitate crystal form A of the compound of formula I.
[0055] In step (1), the mixing should be performed below the boiling point of solvent 1, preferably at 0-80°C; preferably at 20-50°C; more preferably at 30-50°C.
[0056] In step (1), the mixing ratio (weight to volume ratio) of the crud...
Embodiment 1
[0082] Preparation of crude compound I
[0083] With reference to the preparation method reported in the document J.Org.Chern.2004, 69, 1890-1902, (1R, 2R, 3aS, 9aS)-2,3,3a,4,9,9a-hexahydro-1-[( 3S)-3-Hydroxyoctyl]-1H-phenyl[f]indene-2,5-diol was used as the starting material, and 41 g of crude compound I was obtained without purification.
Embodiment 4
[0089] Preparation of compound I crystal form A
[0090] In a 25ml eggplant-shaped bottle, add the compound I crude product (1.0g) and methanol (1.0ml) obtained in Example 1, warm up to 30°C and dissolve to form a homogeneous solution, then slowly add pure water (0.6ml), and cool down to Stir at 5°C for 10 h, filter, wash with 10% aqueous methanol at 5°C for 2-3 times, and dry to obtain 0.91 g of crystalline solid. X-raypowderdiffraction pattern see figure 1 , differential scanning calorimetry (DSC) chart see figure 2 , see the infrared spectrum image 3 , HPLC purity 99.90%. Organic residue: methanol 0.04% (mass yield: 91%)
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a crystal form A, a preparation method and application of a compound with a structural formula shown as a formula I. An X-raypowderdiffraction graph (XRPD) of the crystal form A shows characteristic peaks at the following 2theta angles: 2.9 + / - 0.2 DEG, 13.6 + / - 0.2 DEG, 17.3 + / - 0.2 DEG and 18.6 + / - 0.2 DEG.
Description
technical field [0001] The invention relates to the field of chemical pharmacy, in particular to a crystal form of a prostaglandin analogue and a preparation method and use thereof. Background technique [0002] Treprostinil (UT15, Treprostinil) is a new class of drugs for the treatment of pulmonary arterial hypertension. Its structure is as shown in formula I: [0003] [0004] Pulmonary arterial hypertension (PAH) is a disease characterized by vasospasm, intimal hyperplasia and remodeling of pulmonary arterioles. Vascular proliferation and remodeling of pulmonary arterioles lead to a progressive increase in pulmonary vascular resistance, eventually leading to right ventricular failure and death. [0005] Epoprostenol (Flolan) is the first prostacyclindrug approved by the US Food and Drug Administration (FDA) for the treatment of PAH. The half-life of epoprostenol in the circulation is about 3 to 5 minutes, and continuous intravenous administration is required, and i...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.